Tests VX-880 in adults with type 1 diabetes who had a kidney transplant
Tests VX-880 in adults with type 1 diabetes who received a kidney transplant.
Plain-language title generated from the registry record
Registry title: An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
Key facts
- Where
- Toronto and Vancouver, CanadaSee the 2 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06832410, who can take part
Where in Canada
- Toronto General Hospital - EndocrinologyToronto, CanadaTaking people
- Vancouver General Hospital, Gordon and Leslie Diamond Health Care CentreVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vertex Pharmaceuticals Incorporated
- Trial code
- NCT06832410
- Record updated
- 23 March 2026
- Original description
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.Read full original descriptionShow less
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Inclusion: Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence; Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks; Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study.
Exclusion: Prior islet cell transplant, organ transplant (other than kidney transplant), or cell therapy, except prior pancreatic graft that failed within the first 4 weeks; Participants had >1 kidney transplant procedure; Other protocol defined Inclusion/Exclusion criteria may apply.